Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group.
Our objective was to determine whether oral etoposide and cisplatin combination (EoP) is superior to paclitaxel in the treatment of advanced breast cancer (ABC) patients pretreated with anthracyclines. From December 1997 to August 2003, 201 patients were randomised, 100 to EoP and 101 to paclitaxel arms. Four patients in each arm were ineligible. The doses of etoposide and cisplatin were 50 mg p.o. twice a day for 7 days and 70 mg m(-2) intravenously (i.v.) on day 1, respectively, and it was 175 mg m(-2) on day 1 for paclitaxel. Both treatments were repeated every 3 weeks. A median of four cycles of study treatment was given in both arms. The response rate obtained in the EoP arm was significantly higher (36.3 vs 22.2%; P=0.038). Median response duration was longer for the EoP arm (7 vs 4 months) (P=0.132). Also, time to progression was significantly in favour of the EoP arm (5.5 vs 3.9 months; P=0.003). Median overall survival was again significantly longer in the EoP arm (14 vs 9.5 months; P=0.039). Toxicity profile of both groups was similar. Two patients in each arm were lost due to febrile neutropenia. The observed activity and acceptable toxicity of EoP endorses the employment of this combination in the treatment of ABC following anthracyclines.
Icli
F
F
Department of Medical Oncology, Ibni Sina Hospital, Ankara University School of Medicine, Ankara 06100, Turkey. ficli@dialup.ankara.edu.tr
Akbulut
H
H
Uner
A
A
Yalcin
B
B
Baltali
E
E
Altinbas
M
M
Coşkun
S
S
Komurcu
S
S
Erkisi
M
M
Demirkazik
A
A
Senler
F C
FC
Sencan
O
O
Büyükcelik
A
A
Boruban
C
C
Onur
H
H
Zengin
N
N
Sak
S D
SD
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome; D014421:Turkey
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D017239:Paclitaxel; D002945:Cisplatin
Cancer Chemother Pharmacol. 1994;33(6):527-9
8137464
J Clin Oncol. 1999 May;17(5):1413-24
10334526
Cancer Treat Rev. 1993;19 Suppl C:27-33
8221713
J Clin Oncol. 1995 Aug;13(8):2056-65
7543562
Cancer. 1991 Jan 1;67(1 Suppl):266-70
1984826
J Clin Oncol. 1996 Jun;14(6):1858-67
8656254
Cancer. 1990 Feb 1;65(3):418-21
2297632
Tumori. 1988 Apr 30;74(2):191-3
3368973
Med Pediatr Oncol. 2000 Jan;34(1):10-3
10611578
Tumori. 1995 Jul-Aug;81(4):241-4
8540119
Am J Clin Oncol. 1996 Apr;19(2):125-31
8610634
Breast Cancer Res Treat. 1995 May;34(2):185-9
7647335
J Clin Oncol. 2005 Aug 20;23(24):5542-51
16110015
Chemioterapia. 1986 Apr;5(2):125-7
3518965
J Surg Oncol. 1992 Aug;50(4):251-3
1640710
J Clin Oncol. 1994 May;12(5):986-91
8164052
Am J Clin Oncol. 1989 Feb;12(1):53-6
2643295
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1493-8
498148
Ann Oncol. 2001 Jul;12(7):1011-3
11521785
Cancer. 1995 Dec 15;76(12):2485-90
8625074
Br J Cancer. 2002 May 6;86(9):1367-72
11986765
Semin Oncol. 1989 Aug;16(4 Suppl 6):110-5
2669132
Eur J Cancer. 1999 Aug;35(8):1194-201
10615229
Eur J Cancer Clin Oncol. 1986 Jul;22(7):761-4
3770033
Br J Cancer. 2002 Nov 18;87(11):1210-5
12439707
J Clin Oncol. 2004 Jun 1;22(11):2061-8
15169793
J Clin Oncol. 1991 Apr;9(4):664-9
2066763